Trials and tribulations - interpreting clinical trials in IBD

Clinical Dilemmas in Inflammatory Bowel Disease

Volumn , Issue , 2007, Pages 81-84

  Carty, Elizabeth ^a   Rampton, David ^b  

^a WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Genotype; Heterogeneity; Natural history; Stratification; Tribulations

Indexed keywords

EID: 68949206801     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470750827.ch23     Document Type: Chapter

References (22)

1. Feagan BG, McDonald JW, Koval JJ. Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trials. Gastroenterology 1996; 110:275-83.
2. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002; 122: 512-30.
3. Moher D, Schulz KF, Altman DG. The CONSORT statement:revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-4.
4. Brzinski A, Lashner BA. Natural history of Crohn’s disease. In: Allan RN, Rhodes JM, et al. (eds.) Inflammatory Bowel Diseases, 3rd edn. Churchill Livingstone, 1997: 475-86.
5. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001; 48: 571-7.
6. Tremaine WJ. Failure to yield: drug resistance in inflammatory bowel disease. Gastroenterology 2002; 122: 1165-7.
7. Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology 2001; 120: 1347-55.
8. Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease. Am J Gastroenterol 2002; 97:1458-62.
9. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizmab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005; 129:807-18.
10. Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn’s disease. Gastroenterology 1990; 98: 1123-8.
11. Belluzzi A, Brignola C, Campieri M, et al. Effect of an entericcoated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med 1996; 334: 1557-60.
12. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
13. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med 1994; 331: 394-8.
14. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978; 13: 833-7.
15. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43: 29-32.
16. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 439-44.
17. Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet 1980; 1: 514.
18. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994; 35: 231-5.
19. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology 1994; 106:287-96.
20. Saverymuttu SH, Camilleri M, Rees H, et al. Indium-111 granulocyte scanning in the assessment of disease extent and activity in inflammatory bowel disease: a comparison of colonoscopy, histology and fecal indium-111 excretion. Gastroenterology 1986; 90: 1121-8.
21. Baron J, Connell A, Leonard-Jones A. Variation between observers in describing mucosal changes in proctocolitis. BMJ 1964; 1: 89-92.
22. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990; 99: 956-63.